Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria

Eculizumab is first-line treatment for paroxysmal nocturnal hemoglobinuria (PNH); however, approximately 11%-27% of patients may experience breakthrough hemolysis (BTH) on approved doses of eculizumab. Ravulizumab, a new long-acting C5 inhibitor with a four-times longer mean half-life than eculizum...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Robert A. Brodsky, Régis Peffault de Latour, Scott T. Rottinghaus, Alexander Röth, Antonio M. Risitano, Ilene C. Weitz, Peter Hillmen, Jaroslaw P. Maciejewski, Jeff Szer, Jong Wook Lee, Austin G. Kulasekararaj, Lori Volles, Andrew I. Damokosh, Stephan Ortiz, Lori Shafner, Peng Liu, Anita Hill, Hubert Schrezenmeier
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Ferrata Storti Foundation 2020-01-01
Edice:	Haematologica
On-line přístup:	https://haematologica.org/article/view/9614
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!